{"entity":{"id":"elispot","kind":"term","name":"ELISpot secretion assays","aka":["ELISpot","enzyme-linked immunospot","IFN-gamma ELISpot"],"tldr":"This test records spots where sampled cells release a chosen substance. A spot count describes secretion under the test conditions; other assays address recognition or killing.","summary":"The original enzyme-linked immunospot method counted antibody-secreting cells; cytokine versions are used to examine stimulated immune-cell responses. Cancer Vaccine Consortium proficiency panels showed that sample handling, protocol choices and plate reading affected results. A result needs the measured molecule, stimulation, cell input, background and reporting rule. A positive secretion response alone does not show that the sampled cells recognize or kill an unmodified tumor.","asOf":"2026-11-10","links":[{"label":"A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.","url":"https://doi.org/10.1016/0022-1759(83)90308-3"},{"label":"Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).","url":"https://doi.org/10.1007/s00262-007-0380-6"},{"label":"Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.","url":"https://doi.org/10.1186/1471-2172-9-9"},{"label":"The role of IFN-γ Elispot assay in HIV vaccine research","url":"https://doi.org/10.1038/nprot.2009.7"},{"label":"Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates","url":"https://doi.org/10.1038/s41434-020-00214-w"},{"label":"ELISPOT Assay to Measure Peptide-specific IFN-γ Production.","url":"https://pubmed.ncbi.nlm.nih.gov/34541071/"}],"tags":[],"related":["intracellular-cytokine-staining","immune-cytotoxicity-assays","pbmc-specimens"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Method card, what it measures: cells that secrete a chosen molecule, most often interferon gamma, under defined stimulation, counted as spots on an antibody-coated membrane. How: capture antibodies hold the released molecule near the cell, the cells are removed and detection reagents make localised spots visible. Input: viable cells, often PBMCs, allocated to the test. Prior culture expansion changes the measured population, and the cells are removed before the membrane spots are read. Output: spot-forming units per stated number of input cells, with background handling stated. Thresholds: response and quality rules fixed in advance for that assay and study, so one paper's positivity rule is not imported into another laboratory's report. Failure modes: high background, dead cells, weak stimulation, merged spots, inconsistent counting or failed controls. It cannot tell each receptor's target, natural tumour recognition, safety in healthy tissue or clinical benefit.","Fictional arithmetic: wells with 100,000 input cells give 30 spots after peptide stimulation and 5 spots with vehicle. Background-subtracted, that is 30 minus 5 = 25 spots per 100,000 cells, or 250 spot-forming units per million input cells. This is an arithmetic summary and not a positivity cut-off, replicates, positive controls and a prespecified response rule still apply, and in mixed PBMCs it is not the frequency of a particular T-cell subset. If the cells came from an expanded culture, the number describes the cultured cells and not the responding fraction of the original blood draw.","What the evidence does and does not support: the interferon gamma ELISpot is described as measuring the difference in the number of cells secreting the molecule with and without peptide, and interferon gamma is produced predominantly by natural killer and natural killer T cells as well as Th1 CD4 and CD8 effector T cells, so a mixed-cell spot does not by itself name the responding cell (Wykes and Renia protocol). In HIV vaccine research robust ELISpot responses were induced in a phase IIb trial that lacked efficacy, which challenged the assay's predictive power (Streeck 2009), and a validation in cynomolgus monkeys for responses to viral vector antigens (Yang 2022) validates that preparation and species and not cancer efficacy. Peptide added to cells can bypass the tumour's own processing and presentation, so a peptide response needs a separate bridge to natural tumour recognition.","Receptor sequencing asks which receptor sequences are represented and in what relative abundance. ELISpot asks how many input cells release the chosen molecule under the stated stimulation. An expanded sequence does not establish that it caused a spot, and a spot in mixed cells does not identify a receptor sequence. Connecting identity to recognition or killing requires additional experiments with suitable controls.","Spot size or intensity is not a measure of target-cell killing. A negative result remains bounded by the number and condition of input cells, the stimulus, chosen secreted molecule, culture history and response rule; it is not a census of every responding cell in the body. Assay reproducibility and a cancer-treatment benefit claim need separate evidence."],"category":"Immunology"},"route":"/terms/elispot/","neighbours":{"term":[{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immune-cytotoxicity-assays","kind":"term","name":"Immune-cell cytotoxicity assays","route":"/terms/immune-cytotoxicity-assays/"},{"id":"immunogenicity-versus-efficacy","kind":"term","name":"Immunogenicity and clinical efficacy","route":"/terms/immunogenicity-versus-efficacy/"},{"id":"intracellular-cytokine-staining","kind":"term","name":"Intracellular cytokine staining","route":"/terms/intracellular-cytokine-staining/"},{"id":"pbmc-specimens","kind":"term","name":"Peripheral blood mononuclear cell specimens","route":"/terms/pbmc-specimens/"}]}}